CA
VRTX icon

CSM Advisors’s Vertex Pharmaceuticals VRTX Stock Holding History

CSM Advisors’s Portfolio VRTX Stock Details VRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.04M Sell
6,133
-4,705
-43% -$2.09M 0.06% 282
2026
Q1 		$4.84M Buy
+10,838
New +$5.05M 0.12% 199

Other funds holding VRTX

Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

CSM Advisors's VRTX Position: Q2 2026 in Review

CSM Advisors reduced its Vertex Pharmaceuticals (VRTX) stake by 43% in Q2 2026, selling an estimated $2.09M and leaving 6,133 shares worth $3.04M. The position accounts for 0.06% of the portfolio, ranked #282.

CSM Advisors first reported a position in VRTX in Q1 2026 and has held it in 2 quarters since. The position peaked at $4.84M in Q1 2026. 1,747 funds tracked by Wall St. Rank hold VRTX as of Q2 2026.

  • CSM Advisors held 6,133 shares of Vertex Pharmaceuticals worth $3.04M as of Q2 2026.
  • CSM Advisors sold 4,705 Vertex Pharmaceuticals shares in Q2 2026, an estimated $2.09M.
  • Vertex Pharmaceuticals made up 0.06% of CSM Advisors's portfolio in Q2 2026, its #282 holding.
  • CSM Advisors first reported a position in Vertex Pharmaceuticals in Q1 2026 and has held it in 2 quarters since.
  • CSM Advisors's Vertex Pharmaceuticals position peaked at $4.84M in Q1 2026.
  • 1,747 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q2 2026.

Based on CSM Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.